Details of the Drug Combination

General Information of Drug Combination (ID: DCZKJEZ)

Drug Combination Name
Rituximab Bevacizumab
Indication
Disease Entry Status REF
Non-hodgkin lymphoma; Lymphoma Phase 1 [1]
Component Drugs Rituximab   DM1YVZT Bevacizumab   DMSD1UN
Antibody Monoclonal antibody

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Rituximab
Disease Entry ICD 11 Status REF
Central nervous system non-hodgkin lymphoma N.A. Approved [2]
Eosinophilic granulomatosis with polyangiitis 4A44.A2 Approved [3]
Hepatosplenic T-cell lymphoma N.A. Approved [4]
Idiopathic thrombocytopenic purpura 3B64.10 Approved [5]
Large granular lymphocytic leukemia 2A90.1 Approved [6]
Leukemia N.A. Approved [7]
Lupus nephritis 4A40.0Y Approved [8]
Lymphoproliferative syndrome N.A. Approved [9]
Lymphosarcoma N.A. Approved [10]
MALT lymphoma N.A. Approved [11]
Nodal marginal zone lymphoma 2A85.0 Approved [12]
Non-hodgkin lymphoma 2B33.5 Approved [13]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [14]
Prolymphocytic leukaemia 2A82.1 Approved [15]
Recurrent adult burkitt lymphoma 2A85.6 Approved [16]
Small intestine lymphoma N.A. Approved [17]
Small lymphocytic lymphoma 2A82.0 Approved [18]
Splenic marginal zone lymphoma N.A. Approved [19]
Testicular lymphoma N.A. Approved [20]
Thrombotic thrombocytopenic purpura 3B64.14 Approved [21]
Waldenstrom macroglobulinemia 2A85.4 Approved [22]
Pemphigus vulgaris EB40 Phase 3 [23]
Haematological malignancy 2B33.Y Phase 1 [24]
B-cell neoplasm N.A. Investigative [25]
Rituximab Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN . [49]
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN . [50]
------------------------------------------------------------------------------------
Rituximab Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases ADR [51]
Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A) OTOWXCF3 FCG3A_HUMAN Increases Response [52]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases ADR [51]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases ADR [51]
------------------------------------------------------------------------------------
Indication(s) of Bevacizumab
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [26]
Adult acute monocytic leukemia N.A. Approved [14]
Biliary tract cancer 2C17 Approved [27]
Childhood acute megakaryoblastic leukemia N.A. Approved [14]
Cholangiocarcinoma 2C12.10 Approved [28]
Colon adenocarcinoma N.A. Approved [29]
Colorectal carcinoma N.A. Approved [30]
Esophageal disorder N.A. Approved [31]
Glioblastoma 2A00 Approved [32]
Glioblastoma of brain 2A00.00 Approved [33]
Hemangioblastoma N.A. Approved [34]
Intracranial meningioma N.A. Approved [35]
Lung adenocarcinoma N.A. Approved [36]
Malignant epithelial tumor of ovary N.A. Approved [37]
Metastatic colorectal cancer 2B91 Approved [13]
Non-small-cell lung cancer 2C25.Y Approved [38]
Rectal adenocarcinoma 2B92 Approved [39]
Von hippel-lindau disease 5A75 Approved [40]
Colorectal cancer 2B91.Z Phase 3 [41]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [42]
Brain metastases 2D50 Phase 2 [41]
Lung cancer 2C25.0 Phase 1 [41]
Solid tumour/cancer 2A00-2F9Z Phase 1 [43]
Ovarian cancer 2C73 Application submitted [43]
Adult glioblastoma N.A. Investigative [44]
Colon cancer 2B90.Z Investigative [45]
Fallopian tube cancer 2C74 Investigative [46]
Hereditary hemorrhagic telangiectasia LA90.00 Investigative [47]
Lung large cell carcinoma N.A. Investigative [48]
Bevacizumab Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Inhibitor [53]
HUMAN vascular endothelial growth factor (VEGF) TT140V6 VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN Inhibitor [42]
------------------------------------------------------------------------------------
Bevacizumab Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Mastermind-like protein 2 (MAML2) OT1TSVAR MAML2_HUMAN Increases ADR [54]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) OT25JBA3 F263_HUMAN Increases ADR [54]
TGF-beta receptor type-2 (TGFBR2) OT3P7GZP TGFR2_HUMAN Increases ADR [54]
Beta-parvin (PARVB) OT9OGVWX PARVB_HUMAN Increases ADR [54]
Mitochondrial peptide methionine sulfoxide reductase (MSRA) OTBS15SD MSRA_HUMAN Increases ADR [54]
Synaptic vesicle glycoprotein 2C (SV2C) OTIH108W SV2C_HUMAN Increases ADR [54]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

References

1 FDA Drug Development and Drug Interactions
2 How we treat primary central nervous system lymphoma. ESMO Open. 2021 Aug;6(4):100213.
3 Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019 Oct;68(4):430-436.
4 Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. Diagn Pathol. 2014 Mar 12;9:58.
5 Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
6 Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
7 Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80.
8 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723.
9 Autoimmune lymphoproliferative syndrome: A disorder of immune dysregulation. Autoimmun Rev. 2023 Nov;22(11):103442.
10 Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18(4):465-71.
11 Diagnosis and Treatment for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. J Clin Med. 2022 Dec 23;12(1):120.
12 Nodal marginal zone lymphoma. Leuk Lymphoma. 2014 Jun;55(6):1240-50.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
15 B and T cell prolymphocytic leukaemia. Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228.
16 Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy. Leuk Lymphoma. 2023 Mar;64(3):586-596.
17 Metachronous primary cancer of the tongue and malignant lymphoma of the small intestine: A case report. Medicine (Baltimore). 2021 Feb 19;100(7):e24806.
18 Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043.
19 Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol. 2017 Mar-Jun;30(1-2):139-148.
20 First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011 Jul 10;29(20):2766-72.
21 Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536.
22 Waldenstr?m macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-358.
23 ClinicalTrials.gov (NCT02383589) A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris. U.S. National Institutes of Health.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6780).
25 Diffuse Large B-Cell Lymphoma and Related Entities. Dtsch Arztebl Int. 2023 Apr 28;120(17):289-296.
26 Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. Rare Tumors. 2019 May 14;11:2036361318825413.
27 Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opin Investig Drugs. 2021 Apr;30(4):411-418.
28 Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565.
29 Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. Immunotherapy. 2023 Feb;15(3):127-133.
30 Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508.
31 Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):229.
32 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.
33 Synchronous glioblastoma and brain metastases: illustrative case. J Neurosurg Case Lessons. 2022 Mar 21;3(12):CASE21714.
34 Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma. Cureus. 2022 Dec 17;14(12):e32624.
35 The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review. Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203.
36 International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85.
37 Gynecologic cancer in pregnancy. Gynecol Oncol. 2020 Jun;157(3):799-809.
38 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.
39 Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as?preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term?results. BMC Cancer. 2020 Nov 27;20(1):1164.
40 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. J Nucl Med. 2016 Aug;57(8):1244-50.
41 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
42 ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
43 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
44 Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963.
45 Colon cancer. Crit Rev Oncol Hematol. 2010 May;74(2):106-33.
46 OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45.
47 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018 Sep;103(9):1433-1443.
48 Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94.
49 [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
50 Clinical pipeline report, company report or official report of Genentech (2009).
51 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
52 FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11.
53 FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
54 Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer. 2014 Sep 9;111(6):1241-8. doi: 10.1038/bjc.2014.430. Epub 2014 Aug 12.